Alamar Biosciences

Alamar Biosciences (Ticker: ALMR US) provides technology for detecting and analyzing proteins and measuring multiple biomarkers. Its NULISA technology and ARGO HT System support sensitive analysis of multiple biomarkers. Founded in 2018, the company is headquartered in Fremont, California. Planned uses of IPO proceeds included general corporate purposes, working capital, operating expenses and capital expenditures.

The scheduled listing date on Nasdaq was April 17, 2026. The proposed offering comprises 9,375,000 shares at an indicative price range of $15.00–17.00 per share. At the indicative range midpoint, the base offering would represent $150.00 million in gross proceeds, excluding any unexercised over-allotment.

J.P. Morgan, Bank of America and TD Cowen were joint bookrunners. J.P. Morgan also served as stabilization agent and handled bill-and-deliver responsibilities.